EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics Lic...
A director at Monolithic Power Systems Inc sold 20,231 shares at 829.101USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Following 2Q results, momentum seems most favorable for the companies below:META (Outperform) - While sentiment was already elevated ahead of the print, 2Q results were strong and guidance for 3Q was encouraging, with expectations for revenue growth ahead of initial St. estimates by ~700bps. Additi
Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Cantor Global Healthcare Conference 2025 at 1:35 p.m. ET on Wednesday, September 3, 20252025 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, September 4, 2025Morgan Stanley 23rd Annual Global Healthcare Conference at 11:30 a.m. ET on Monday, September 8, 2025Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, Sep...
Figure 1. 2Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusAirbnb reported strong 2Q results and provided an in-line outlook for 3Q. Nights and Experiences booked growth in 2Q of +7.4% Y/Y was ~80bps above Street estimates. Revenue and adj. EBITDA were ahead of estimates by
Regeneron Reports Second Quarter 2025 Financial and Operating Results Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA® U.S. net sales decreased 25% to $1.15 billion GAAP EPS increased 3% to $12.81; non-GAAP EPS(a) increased 12% to $12.89FDA approved Lynozyfic™ (linvoseltamab) for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria (CSU)FDA ...
Monolithic Power Systems Announces Results for the Second Quarter Ended June 30, 2025 KIRKLAND, Wash., July 31, 2025 (GLOBE NEWSWIRE) -- Monolithic Power Systems, Inc. (“MPS”) (Nasdaq: MPWR), a fabless global company that provides high-performance, semiconductor-based power electronics solutions, today announced financial results for the quarter ended June 30, 2025. The financial results for the quarter ended June 30, 2025 were as follows: Revenue was $664.6 million for the quarter ended June 30, 2025, a 4.2% increase from $637.6 million for the quarter ended March 31, 2025 and a 31.0% ...
Monolithic Power Systems Provides Earnings Commentary for the Quarter Ended June 30, 2025 KIRKLAND, Wash., July 31, 2025 (GLOBE NEWSWIRE) -- MPS will report its results after the market closes on July 31, 2025 and host a question-and-answer webinar at 2:00 p.m. PT / 5:00 p.m. ET. The live event will be held via a Zoom webcast, which can be accessed at . Q2 2025 Financial Summary (Unaudited)GAAP Q2'25Q1'25Q2'24 QoQ ChangeYoY ChangeRevenue ($k)$664,574$637,554$507,431 Up 4.2%Up 31.0%Gross Margin55.1%55.4%55.3% Down 0.3 ptsDown 0.2 ptsOpex ($k)$201,258$184,471$164,042 Up 9.1%Up 22.7%Ope...
Figure 1. 2Q25 ResultsSources: Company reports, Wedbush estimates, FactSet consensusGuidance: Gross Bookings growth of +10%to +12% Y/Y; Room Nights growth of +4% to +6%Y/Y; Adj. EBITDA of $2.15mm to $2.2mm.2Q results were ahead of expectations. Gross bookings of $46.7B (+12.8% Y/Y) in the quarter w
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.